Search

Your search keyword '"Tonner, Françoise"' showing total 14 results
Start Over Author "Tonner, Françoise"
14 results on '"Tonner, Françoise"'

6. Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis

Author

Hudgens-Haney, Matthew E., primary, Clementz, Brett A., additional, Ivleva, Elena I., additional, Keshavan, Matcheri S., additional, Pearlson, Godfrey D., additional, Gershon, Elliot S., additional, Keedy, Sarah K., additional, Sweeney, John A., additional, Gaudoux, Florence, additional, Bunouf, Pierre, additional, Canolle, Benoit, additional, Tonner, Françoise, additional, Gatti-McArthur, Silvia, additional, and Tamminga, Carol A., additional

Published
2020
Full Text
View/download PDF

7. Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis

Author

Hudgens-Haney, Matthew E, primary, Clementz, Brett A, additional, Ivleva, Elena I, additional, Keshavan, Matcheri S, additional, Pearlson, Godfrey D, additional, Gershon, Elliot S, additional, Keedy, Sarah K, additional, Sweeney, John A, additional, Gaudoux, Florence, additional, Bunouf, Pierre, additional, Canolle, Benoit, additional, Tonner, Françoise, additional, Gatti-McArthur, Silvia, additional, and Tamminga, Carol A, additional

Published
2020
Full Text
View/download PDF

9. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO

Author

Slifstein, Mark, primary, Abi-Dargham, Anissa, additional, Girgis, Ragy R, additional, Suckow, Raymond F, additional, Cooper, Thomas B, additional, Divgi, Chaitanya R, additional, Sokoloff, Pierre, additional, Leriche, Ludovic, additional, Carberry, Patrick, additional, Oya, Shunichi, additional, Joseph, Simon K, additional, Guiraud, Marlène, additional, Montagne, Agnès, additional, Brunner, Valérie, additional, Gaudoux, Florence, additional, and Tonner, Françoise, additional

Published
2019
Full Text
View/download PDF

10. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study

Author

Blume‐Peytavi, Ulrike, primary, Issiakhem, Zahida, additional, Gautier, Stephanie, additional, Kottner, Jan, additional, Wigger‐Alberti, Walter, additional, Fischer, Tobias, additional, Hoffmann, Rolf, additional, Tonner, Françoise, additional, Bouroubi, Athmane, additional, and Voisard, Jean‐Jacques, additional

Published
2018
Full Text
View/download PDF

11. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study.

Author

Blume‐Peytavi, Ulrike, Kottner, Jan, Issiakhem, Zahida, Gautier, Stephanie, Tonner, Françoise, Bouroubi, Athmane, Wigger‐Alberti, Walter, Fischer, Tobias, Hoffmann, Rolf, and Voisard, Jean‐Jacques

Subjects
HAIR growth, BALDNESS, CONFIDENCE intervals, COMPARATOR circuits
Abstract

Summary: Background: Androgenetic alopecia (AGA) is the most common cause of hair loss in men. Topical minoxidil solutions can help to treat AGA but have to be applied continuously to be effective. Objectives: A new minoxidil formulation with improved cosmetic characteristics (DC0120, Pierre‐Fabre Dermatologie) was tested for noninferiority vs a comparator minoxidil product (ALOSTIL®, Johnson & Johnson) in stimulating hair growth in men with AGA. Methods: Two 10 cm2 areas on the scalp of each subject were randomized to receive DC0120, the comparator, or one of their corresponding vehicles, applied twice per day for 16 weeks. Nonvellus target area hair count (TAHC) was measured within treatment areas at baseline (day 1) and after 8 and 16 weeks by digital phototrichogram. Results: Two hundred and twenty subjects were included and randomized, of which 210 completed the study. The mean change in nonvellus TAHC between baseline and week 16 was +22.0 hairs/cm2 (95% CI: 18.1; 25.9) in the DC0120 group and +20.5 hairs/cm2 (95% CI: 16.6; 24.4) in the comparator group. The adjusted mean difference in TAHC changes between the two treatments was +1.5 hairs/cm2 (95% CI −2.3; 5.2), with the lower 95% confidence interval above the noninferiority threshold of −7 hairs/cm2. This indicated that DC0120 was noninferior to the comparator. Both minoxidil treatments also increased nonvellus TAHC compared to vehicle groups at 8 and 16 weeks. No new safety signals were observed. Conclusions: DC0120 was as safe and effective as a similar marketed minoxidil product for stimulating hair growth in men with AGA. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3antagonist, in the treatment of acute exacerbation of schizophrenia

Author

Bitter, Istvan, Lieberman, Jeffrey A., Gaudoux, Florence, Sokoloff, Pierre, Groc, Mélanie, Chavda, Rajeev, Delsol, Cécile, Barthe, Laurence, Brunner, Valérie, Fabre, Carine, Fagard, Marine, Montagne, Agnès, and Tonner, Françoise

Abstract

F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Change from baseline to Day 43 of the Positive and Negative Syndrome Scale (PANSS) total score was the primary outcome. The data from 134 randomized patients (67 per group) were analyzed (efficacy/safety). Using analysis of covariance (ANCOVA) after last observation carried forward (LOCF) imputation (primary analysis), the PANSS total score reduction was statistically significantly greater for F17464 than placebo treated subjects at endpoint (p= 0.014); using ANCOVA with Multiple Imputation (MI) method, the between-group difference was in favor of F17464 but did not reach statistical significance. Differences in PANSS positive and general psychopathology subscale score, Marder positive factor score, PANSS response, and PANSS resolution criteria were also statistically significant in favor of F17464 (pvalues < 0.05) using the LOCF method, with similar results as for the primary analysis using the MI method. Treatment-related adverse events (AEs) were reported in 49.3% and 46.3% of patients on F17464 and placebo, respectively. The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results